ライフサイエンスコーパス: diabetic retinopathy

1 ucoma, age-related macular degeneration, and diabetic retinopathy).

2 r mild, moderate, or severe nonproliferative diabetic retinopathy).

3 cular thickness compared to patients with no diabetic retinopathy.

4 that are characteristic of non-proliferative diabetic retinopathy.

5 ed by compromised vascular integrity such as diabetic retinopathy.

6 articipants with no history of proliferative diabetic retinopathy.

7 eutic billing codes used in the treatment of diabetic retinopathy.

8 s relationship was not seen among those with diabetic retinopathy.

9 ays an important role in the pathogenesis of diabetic retinopathy.

10 ificantly reduced in more advanced stages of diabetic retinopathy.

11 reflect the medical record for patients with diabetic retinopathy.

12 g alteration of the blood-retinal barrier in diabetic retinopathy.

13 ocess is linked to the onset of experimental diabetic retinopathy.

14 neurovascularization (ETS1, HES5, PRDM16) in diabetic retinopathy.

15 deficiency impairs this process and prevents diabetic retinopathy.

16 rovide therapeutic benefits in proliferative diabetic retinopathy.

17 closure, and progression of nonproliferative diabetic retinopathy.

18 h type 1 diabetes and their association with diabetic retinopathy.

19 ths among those with severe nonproliferative diabetic retinopathy.

20 macular microvascular pathology in eyes with diabetic retinopathy.

21 of 10 patients who were diagnosed as having diabetic retinopathy.

22 ciated virus (AAV)-ACE2 prevents or reverses diabetic retinopathy.

23 such as age-related macular degeneration and diabetic retinopathy.

24 fication for tractive retinal detachment and diabetic retinopathy.

25 o the retina and other structural markers of diabetic retinopathy.

26 chanisms and validates druggable targets for diabetic retinopathy.

27 (Akita) mouse is a good model for late-onset diabetic retinopathy.

28 in blood-retinal barrier (BRB) damage during diabetic retinopathy.

29 on to determine the presence and severity of diabetic retinopathy.

30 an type 2 diabetes, the most common cause of diabetic retinopathy.

31 al photography to screen for the presence of diabetic retinopathy.

32 development of PDR and slows progression of diabetic retinopathy.

33 , including Alzheimer's disease, stroke, and diabetic retinopathy.

34 e of Jurkat cells and disease progression in diabetic retinopathy.

35 to retinal complications and vision loss in diabetic retinopathy.

36 million [0.6 million to 13.3 million]), and diabetic retinopathy (2.6 million [0.2 million to 9.9 mi

37 In patients without diabetic retinopathy (2243 by NMFP and 2252 by UWFI), th

38 s (age-related macular degeneration: 34.2 %; diabetic retinopathy: 4.2 %; retinal vein occlusion: 3.8

39 ractive error (60.8%), cataract (20.1%), and diabetic retinopathy (5.2%).

40 f all injections that were for proliferative diabetic retinopathy), 8.3% to treat retinal vein occlus

41 se of vision loss in eye pathologies such as diabetic retinopathy, age-related macular degeneration,

42 applications to retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration,

43 abetic patients without clinical evidence of diabetic retinopathy and 40 eyes of 40 healthy nondiabet

44 patients were recruited (90 patients with no diabetic retinopathy and 90 patients with NPDR) into the

45 causative role of let-7 in nonproliferative diabetic retinopathy and a repressive function of let-7

46 eye disease, a major cause of vision loss in diabetic retinopathy and age-related macular degeneratio

47 permeability are hallmarks of proliferative diabetic retinopathy and age-related macular degeneratio

48 reak similar to human macula-in the study of diabetic retinopathy and diabetic macular edema (DME).

49 eate an algorithm for automated detection of diabetic retinopathy and diabetic macular edema in retin

50 Cataract, glaucoma, diabetic retinopathy and dry eye disease are common with

51 posterior (age-related macular degeneration, diabetic retinopathy and glaucoma) segments of the eye.

52 luid accumulation is similar to that seen in diabetic retinopathy and may represent an important unde

53 In diseases such as proliferative diabetic retinopathy and neovascular age-related macular

54 ortant contributor to the microangiopathy of diabetic retinopathy and nephropathy.

55 he blood-retinal barrier (BRB), as occurs in diabetic retinopathy and other chronic retinal diseases,

56 markers and appears to promote experimental diabetic retinopathy and that Muller cells orchestrate i

57 the association between the diagnosis of any diabetic retinopathy and the refractive status.

58 ty of human diseases including proliferative diabetic retinopathy and wet age-related macular degener

59 ng type 2 diabetes mellitus patients with no diabetic retinopathy and with non-proliferative diabetic

60 proliferative retinopathy, or progression of diabetic retinopathy), and nerve events (a composite of

61 8%) had ocular hypertension, 102 (11.3%) had diabetic retinopathy, and 68 (7.5%) had other retinal ab

62 eases, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degenerati

63 eases, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degenerati

64 ial pancreas technologies, new therapies for diabetic retinopathy, and breakthroughs in laboratory pr

65 is a key determinant in the pathogenesis of diabetic retinopathy, and inhibition of sEH can prevent

66 ts has revolutionized the treatment of nAMD, diabetic retinopathy, and other ischemic retinopathies,

67 These results indicate that diabetic retinopathy, and possibly other diabetic microv

68 as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related macular degene

69 of macular degeneration; 37.3% were aware of diabetic retinopathy; and 25% were not aware of any eye

70 In eyes without diabetic retinopathy, approximately 20% may have ocular

71 -related macular degeneration, glaucoma, and diabetic retinopathy, are ideal candidates for home moni

72 ology's 2012 Preferred Practice Patterns for Diabetic Retinopathy as 91 answerable clinical research

73 ergoing primary vitrectomy for proliferative diabetic retinopathy at 16 different vitreoretinal units

74 s and OCT images obtained from patients with diabetic retinopathy at a single visit between July 1, 2

75 s of pars plana vitrectomy for proliferative diabetic retinopathy, but clinical trial data may not re

76 cess and frequent reminders to patients that diabetic retinopathy can be treated are practical strate

77 udy design in two prospective cohorts of the DIabetic REtinopathy Candesartan Trial (DIRECT): PROTECT

78 Based on results from Diabetic Retinopathy Clinical Research (DRCR) Network Pr

79 The Diabetic Retinopathy Clinical Research Network (DRCR Net

80 egeneration Treatments Trials (CATT) and the Diabetic Retinopathy Clinical Research Network (DRCR.net

81 Diabetic Retinopathy Clinical Research Network (DRCR.net

82 es with and without topical antibiotics from Diabetic Retinopathy Clinical Research Network clinical

83 tilization data at 1-year follow-up from the Diabetic Retinopathy Clinical Research Network Comparati

84 Presence of DME on OCT used Diabetic Retinopathy Clinical Research Network eligibili

85 The Diabetic Retinopathy Clinical Research Network Protocol

86 r the concurrent parallel-group trial by the Diabetic Retinopathy Clinical Research Network testing b

87 mpt and deferred laser treatment arms of the Diabetic Retinopathy Clinical Research Network's Protoco

88 al and high glucose concentrations mimicking diabetic retinopathy conditions in vitro.

89 eceptor disruption on SDOCT in patients with diabetic retinopathy corresponds to areas of capillary n

90 er a healthcare worker told the patient that diabetic retinopathy could be treated (p = 0.005) were i

91 may be easily incorporated in the automated diabetic retinopathy detection algorithms.

92 Diabetic retinopathy, diabetic macular edema (DME), visi

93 l images, which were graded 3 to 7 times for diabetic retinopathy, diabetic macular edema, and image

94 Developing a noninvasive measure of diabetic retinopathy disease progression may provide phy

95 Diabetic retinopathy (DR) affects an estimated 250 milli

96 retinal layers of diabetic patients without diabetic retinopathy (DR) after 1 year of follow-up.

97 o identify factors associated with prevalent diabetic retinopathy (DR) among Chinese American adults

98 he prevalence of and factors associated with diabetic retinopathy (DR) among non-Indigenous and Indig

99 f neurodegeneration in the initial stages of diabetic retinopathy (DR) and 2) the presence of neurode

100 with several human visual disorders, such as diabetic retinopathy (DR) and age-related macular degene

101 The in vivo function of microRNAs (miRs) in diabetic retinopathy (DR) and age-related macular degene

102 Previous studies on the relationship between diabetic retinopathy (DR) and cardiovascular disease (CV

103 of four ocular diseases; cataract, glaucoma, diabetic retinopathy (DR) and dry eye disease (DED) was

104 e projection-resolved (PR) OCTA in eyes with diabetic retinopathy (DR) and healthy eyes.

105 es such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusion (RV

106 he association of OCT-A characteristics with diabetic retinopathy (DR) and systemic risk factors.

107 nd clinical stages leading to vision loss in diabetic retinopathy (DR) are highlighted.

108 abetes in the United States, severe forms of diabetic retinopathy (DR) are significantly associated w

109 : 210 normal (NL), 183 glaucoma (GL), and 18 diabetic retinopathy (DR) at Tilganga Institute of Ophth

110 A diabetic retinopathy (DR) biomarker, tumor necrosis fact

111 prevalence of diabetes, annual screening for diabetic retinopathy (DR) by expert human grading of ret

112 vessels shows multiple vascular hallmarks of diabetic retinopathy (DR) due to BRB disruption.

113 Diabetic retinopathy (DR) has long been recognized as a

114 abetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening.

115 correlations with visual acuity in eyes with diabetic retinopathy (DR) in the absence of diabetic mac

116 Retinal telescreening for evaluation of diabetic retinopathy (DR) in the primary care setting ma

117 evaluate the prevalence and risk factors for diabetic retinopathy (DR) in the Singapore Epidemiology

118 Diabetic retinopathy (DR) incidence/progression was more

119 Importance: Diabetic retinopathy (DR) is a devastating complication

120 Diabetic retinopathy (DR) is characterized by all of the

121 The association between obesity and diabetic retinopathy (DR) is equivocal, possibly owing t

122 Ophthalmic screening to check for diabetic retinopathy (DR) is important to prevent vision

123 Diabetic retinopathy (DR) is one of the leading causes o

124 Diabetic retinopathy (DR) is one of the leading causes o

125 Diabetic retinopathy (DR) is the most common microvascul

126 Early diagnosis of diabetic retinopathy (DR) is vital but challenging.

127 The presence and severity of diabetic retinopathy (DR) may contribute to the risk of

128 ndred twenty-six eyes of 69 patients with no diabetic retinopathy (DR) or mild or moderate nonprolife

129 Importance: The public health success of diabetic retinopathy (DR) screening programs depends on

130 Cox regression after stratifying by baseline diabetic retinopathy (DR) severity and adjusting for age

131 Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy (DR) severity scale (DRSS) grade du

132 2 diabetes mellitus (T2DM) without and with diabetic retinopathy (DR) using a dual optical tweezers

133 Retinopathy Study (ETDRS) letter scores, and diabetic retinopathy (DR) was measured by the standardiz

134 , their results regarding the progression of diabetic retinopathy (DR) were neutral with liraglutide

135 ard exudates (HEs) are the classical sign of diabetic retinopathy (DR) which is one of the leading ca

136 Total of 143 diabetic eyes-27 with no diabetic retinopathy (DR), 47 with nonproliferative DR (

137 Diabetic retinopathy (DR), a major microvascular complic

138 ericytes (RPCs) is a hallmark of early stage diabetic retinopathy (DR), but the mechanism underlying

139 ngiography (OCTA) may have value in managing diabetic retinopathy (DR), but there is limited informat

140 nd randomized controlled trials for managing diabetic retinopathy (DR), including diabetic macular ed

141 onetheless, under chronic diseases including diabetic retinopathy (DR), mitophagy dysregulation and N

142 ous forms of exudative maculopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO),

143 The aetiology of diabetic retinopathy (DR), the leading cause of blindnes

144 eir mechanism of action were investigated in diabetic retinopathy (DR).

145 ttle is known about their risk of developing diabetic retinopathy (DR).

146 role in the pathogenesis and progression of diabetic retinopathy (DR).

147 perimental rat streptozotocin (STZ) model of diabetic retinopathy (DR).

148 several pathophysiological deficits found in diabetic retinopathy (DR).

149 ith BRB breakdown and macular oedema such as diabetic retinopathy (DR).

150 ion is an early event in the pathogenesis of diabetic retinopathy (DR).

151 Macular ischemia is a key feature of diabetic retinopathy (DR).

152 ays an important role in the pathogenesis of diabetic retinopathy (DR).

153 induced retinal inflammation associated with diabetic retinopathy (DR).

154 have not identified any robust risk loci for diabetic retinopathy (DR).

155 creasing diabetic microvasculopathy based on diabetic retinopathy (DR).

156 he decision-making processes before treating diabetic retinopathy (DR).

157 nagement (DSM) may affect his or her risk of diabetic retinopathy (DR); however, few studies have exa

158 age-related macular degeneration (Dr. Fine), diabetic retinopathy (Dr. Goldberg), and retinal detachm

159 elated macular degeneration [AMD], cataract, diabetic retinopathy [DR], and glaucoma) and the overlap

160 To determine the direct cost of diabetic retinopathy [DR], evaluating our screening prog

161 lesions representing the classic hallmark of diabetic retinopathy, establishing a model for assessing

162 4 lines and >/=2 lines of Early Treatment of Diabetic Retinopathy (ETDRS)-letters, respectively.

163 change in visual acuity (VA; Early Treatment Diabetic Retinopathy [ETDRS] letters) from baseline to 2

164 ropean Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) study (NCT01726075).

165 Standard diabetic retinopathy evaluation and nondiabetic findings

166 Screening for diabetic retinopathy every 2.5 years is cost-effective,

167 Fundus photographs from 7 Early Treatment Diabetic Retinopathy fields were graded in a masked mann

168 formed the first prospective cohort study of diabetic retinopathy from Sub-Saharan Africa over 24 mon

169 age-related macular degeneration, cataracts, diabetic retinopathy, glaucoma, and intraocular cancers.

170 y higher level of mean serum uric acid in no diabetic retinopathy group (p = 0.004 respectively).

171 Proliferative diabetic retinopathy has been managed by panretinal lase

172 Screening for diabetic retinopathy has the potential to increase the n

173 up is crucial to the effective management of diabetic retinopathy, however, follow-up rates are often

174 are likely important for the development of diabetic retinopathy; however, the interplay between the

175 efractive error and the likelihood of having diabetic retinopathy in a cross-sectional, population-ba

176 atus is associated with lower odds of having diabetic retinopathy in the South Korean population.

177 rent recommendations regarding screening for diabetic retinopathy include annual dilated retinal exam

178 Diabetic retinopathy is a common complication of diabete

179 Diabetic retinopathy is a leading cause of blindness, bu

180 Diabetic retinopathy is a major cause of irreversible vi

181 Diabetic retinopathy is a microvascular complication of

182 billing claim codes used during the care of diabetic retinopathy is a necessary precursor to fully u

183 Diabetic retinopathy is an important cause of blindness

184 Diabetic retinopathy is the commonest microvascular comp

185 Proliferative diabetic retinopathy is the most common cause of severe

186 ), moderate (27.2%), severe nonproliferative diabetic retinopathy (NPDR) (45.5%).

187 ome of (1) progression from nonproliferative diabetic retinopathy (NPDR) to PDR based on graded fundu

188 Non proliferative diabetic retinopathy (NPDR) was found in 69%, proliferat

189 no retinopathy, 21 eyes had nonproliferative diabetic retinopathy (NPDR) without macular edema, 20 ey

190 25.4% for mild and moderate nonproliferative diabetic retinopathy (NPDR), and 2.3% for severe NPDR or

191 betic retinopathy and with non-proliferative diabetic retinopathy (NPDR).

192 diabetic patients who have non-proliferative diabetic retinopathy (NPDR).

193 phy (OCTA) in patients with nonproliferative diabetic retinopathy (NPDR).

194 vision impairment at all ages in 2015 due to diabetic retinopathy (odds ratio 2.52 [1.48-3.73]) and c

195 egatively associated with development of any diabetic retinopathy (odds ratio [OR] 0.42; 95% confiden

196 The role of diabetic retinopathy on the relationship between NSAID u

197 probability of progression to proliferative diabetic retinopathy or clinically significant macular e

198 ression from no retinopathy to proliferative diabetic retinopathy or clinically significant macular e

199 e likelihood of progression to proliferative diabetic retinopathy or clinically significant macular e

200 to December 31, 2014, using the search terms diabetic retinopathy OR macular edema AND stroke OR cere

201 uivalent, there was a 30% increase of having diabetic retinopathy (OR 1.30; 95% CI, 1.08-1.58).

202 de (FAc) on the progression to proliferative diabetic retinopathy (PDR) and the impact of FAc on chan

203 nd risk factors for developing proliferative diabetic retinopathy (PDR) and vitreous hemorrhage (VH).

204 macular degeneration (AMD) and proliferative diabetic retinopathy (PDR) are one of the major causes o

205 pathy (NPDR) was found in 69%, proliferative diabetic retinopathy (PDR) in 31% and advanced diabetic

206 ts that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated with panretin

207 Proliferative diabetic retinopathy (PDR) is a common cause of blindnes

208 nal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) may lead to peripheral field

209 out macular edema, 20 eyes had proliferative diabetic retinopathy (PDR) without macular edema, and 27

210 trectomy, while in a case with proliferative diabetic retinopathy (PDR), vitrectomy was resorted for

211 oagulation (PRP) when managing proliferative diabetic retinopathy (PDR), with or without concomitant

212 s hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).

213 evere manifestations of active proliferative diabetic retinopathy (PDR).

214 ), and 2.3% for severe NPDR or proliferative diabetic retinopathy (PDR).

215 abetic macular edema [DME] and proliferative diabetic retinopathy [PDR]) have a higher risk of CVD wi

216 ity of the algorithm for detecting referable diabetic retinopathy (RDR), defined as moderate and wors

217 nopathy (RDR), defined as moderate and worse diabetic retinopathy, referable diabetic macular edema,

218 Despite recent advances in therapeutics, diabetic retinopathy remains a leading cause of vision i

219 Improvement in the treatment of diabetic retinopathy requires a better understanding of

220 allmark of CADASIL and other SVDs, including diabetic retinopathy, resulting in vascular instability.

221 were assessed including, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular ho

222 in the incidence of PME among patients with diabetic retinopathy (RR 1.06, 95% 0.81-1.38).

223 significant in contralateral PCME (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (

224 erwent nonmydriatic fundus photography for a diabetic retinopathy screening examination.

225 To evaluate self-reported adherence to diabetic retinopathy screening examinations among diabet

226 d group of patients from the community-based diabetic retinopathy screening register were identified;

227 Results: Diabetic retinopathy screening was completed in 949 adul

228 Worse baseline levels of diabetic retinopathy severity (Early Treatment Diabetic

229 ctors influence >/=2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) score at week

230 can and 7-field fundus photography using the Diabetic Retinopathy Severity Scale.

231 tigate the clinical importance of changes in diabetic retinopathy severity score (DRSS) in patients w

232 comes included BCVA, safety assessments, and Diabetic Retinopathy Severity Score (DRSS).

233 The 2-year incidence of sight-threatening diabetic retinopathy (STDR) for subjects with level 10 (

234 euro482.85 +/- 35.14; per sight-threatening diabetic retinopathy [STDR] patient, euro1528.26 +/- 114

235 ty (BCVA) of 63 approximated Early Treatment Diabetic Retinopathy Study (approxETDRS) letters (range,

236 ng as compared with standard Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field photographs (

237 r a 2-year period for serial Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected VA, SD

238 impact of FAc on changes in Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy

239 al acuity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart remained un

240 Diabetic status with matched Early Treatment Diabetic Retinopathy Study (ETDRS) grading also was mand

241 of patients with 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letter score change,

242 cuity (BCVA) was measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores, and di

243 le of Resolution (logMAR) or Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores.

244 nt in visual acuity was 12.5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters.

245 provement [<5, 5-9, or >/=10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] in BCVA).

246 as lower in patients with Early Treatment of Diabetic Retinopathy Study (ETDRS) level 20-35 than in p

247 calculated for each of the 9 Early Treatment Diabetic Retinopathy Study (ETDRS) macular subfields.

248 cuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol.

249 easured using the electronic Early Treatment Diabetic Retinopathy Study (ETDRS) protocol; total anter

250 (CT) maps, according to the Early Treatment Diabetic Retinopathy Study (ETDRS) sectors.

251 ssment through week 24 of Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) an

252 sual acuity (VA) (median and Early Treatment Diabetic Retinopathy Study [ETDRS] of 55 letters or bett

253 Early Treatment Diabetic Retinopathy Study BCVA and spectral-domain opti

254 color fundus photography and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity.

255 isual acuity (VA) was 4/4 on Early Treatment Diabetic Retinopathy Study charts (ETDRS), on the retina

256 sual acuity (VA) measured on Early Treatment Diabetic Retinopathy Study charts, injection episodes, a

257 The Early Treatment Diabetic Retinopathy Study criteria were used to confirm

258 us photography of 7 standard Early Treatment Diabetic Retinopathy Study fields.

259 visual acuity of at least 72 Early Treatment Diabetic Retinopathy Study letter score (20/40 Snellen e

260 of all eyes was 47.8 (16.9) Early Treatment Diabetic Retinopathy Study letter score (approximately 2

261 n BCVA change from baseline (Early Treatment Diabetic Retinopathy Study letters +/- standard deviatio

262 A score at baseline, 54 [16] Early Treatment Diabetic Retinopathy Study letters [Snellen equivalent a

263 There was a gain of 2.76 Early Treatment Diabetic Retinopathy Study letters at 6 months (p = 0.15

264 argin was prespecified as -5 Early Treatment Diabetic Retinopathy Study letters.

265 rovement [<5, 5-9, or >/=10; Early Treatment Diabetic Retinopathy Study letters] in BCVA) after treat

266 es into categories of no DR (Early Treatment Diabetic Retinopathy Study levels 10-15; n = 154), mild

267 BCVA) for distance using the Early Treatment Diabetic Retinopathy Study protocol from February 1, 201

268 rlie House adaptation of the Early Treatment Diabetic Retinopathy Study protocol.

269 with the drusen area in the Early Treatment Diabetic Retinopathy Study Report (ETDRS) grid (P = 2.29

270 was classified according to Early Treatment Diabetic Retinopathy Study Research Group - report no.

271 41; n = 125), and severe DR (Early Treatment Diabetic Retinopathy Study scale score >/=53; n = 118).

272 ne (n = 189), mild-moderate (Early Treatment Diabetic Retinopathy Study scale score, 20-41; n = 125),

273 abetic retinopathy severity (Early Treatment Diabetic Retinopathy Study scale) were associated with i

274 hotograph grading, using the Early Treatment Diabetic Retinopathy Study severity scale.

275 oundary Segmentation at 9 Early Treatment of Diabetic Retinopathy Study subfields.

276 he best-corrected electronic Early Treatment Diabetic Retinopathy Study VALS (scores range from 0-100

277 ge 20/25-20/200) with a mean Early Treatment Diabetic Retinopathy Study vision of 68.4 letters.

278 relation between the ACC and Early Treatment Diabetic Retinopathy Study visual acuity (r = -0.22) and

279 data entry) including: age, Early Treatment Diabetic Retinopathy Study visual acuity letter score (V

280 Early Treatment Diabetic Retinopathy Study visual acuity, Sloan low-cont

281 eir distribution around the 5 North Carolina Diabetic Retinopathy Telemedicine Network sites by zip c

282 patients participating in the North Carolina Diabetic Retinopathy Telemedicine Network, (2) the locat

283 ophthalmology referral in the North Carolina Diabetic Retinopathy Telemedicine Network.

284 important insights into the pathogenesis of diabetic retinopathy that will further guide us toward r

285 ct of GHRH analogs during the early stage of diabetic retinopathy through their antioxidant and anti-

286 illion (0.5 million to 15.4 million), and by diabetic retinopathy to 3.2 million (0.2 million to 12.9

287 etic macular edema (DME), vision-threatening diabetic retinopathy (VTDR), defined as the presence of

288 ate logistic analysis, 2-step progression of diabetic retinopathy was associated with glycosylated he

289 Diabetic retinopathy was attributed as the main cause of

290 Diabetic retinopathy was based on fundus photograph grad

291 The stage of diabetic retinopathy was determined by clinical examinat

292 Diabetic retinopathy was graded from 2-field retinal ima

293 Diabetic retinopathy was graded using standard fundus ph

294 Diabetic retinopathy was present in 35.8% of people with

295 d or post-laser treated active proliferative diabetic retinopathy were recruited from 22 UK ophthalmi

296 Insured patients with diabetic retinopathy were seen by the practices between

297 CT/EDIC and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) cohorts.

298 T/EDIC) and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).

299 INTERPRETATION: Patients with proliferative diabetic retinopathy who were treated with intravitreal

300 BCVA after cataract surgery in patients with diabetic retinopathy, with no unanticipated safety event